Cabaletta Bio (CABA) Common Equity (2018 - 2025)

Cabaletta Bio has reported Common Equity for 8 years, with the latest figure at $112.1 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 26.44% year-over-year to $112.1 million; the trailing twelve-month figure through Dec 2025 stood at $112.1 million (down 26.44% YoY), and the FY2025 full-year result was $112.1 million, down 26.44% from the prior year.
• Common Equity for Q4 2025 stood at $112.1 million, down from $139.5 million in the prior quarter.
• The five-year high for Common Equity was $236.2 million in Q4 2023, with the low at $85.9 million in Q3 2022.
• Average Common Equity over 5 years is $139.7 million, with a median of $119.8 million recorded in 2021.
• Year-over-year, Common Equity soared 141.92% in 2024 and sank 45.18% in 2025.
• Tracing CABA's Common Equity over 5 years: stood at $118.0 million in 2021, then slipped by 11.39% to $104.5 million in 2022, then surged by 125.98% to $236.2 million in 2023, then tumbled by 35.51% to $152.3 million in 2024, then dropped by 26.44% to $112.1 million in 2025.
• The last three Common Equity figures came in at $112.1 million (Q4 2025), $139.5 million (Q3 2025), and $178.5 million (Q2 2025), per Business Quant data.

Peer Comparison